Investor Presentation

7 November 2026 To To BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400001 Bandra (E), Mumbai – 400051 Scrip Code: 543064 Scrip Symbol: COHANCE Dear Sir/Madam, Sub: Revised Investor Presentation for Q2 and H1 FY27 With reference to the Investor Presentation for Q2 and H1 FY27 submitted on 6 November 2026, the Company has updated the Investor Presentation with certain corrections and alignments for consistency and clarity. Please take the updated version for your record. Thanking you. Yours faithfully, For Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) Sisir K. Mishra Company Secretary & Compliance Officer Encl: as above INVESTOR PRESENTATION Q2 FY2027 November 2026 Disclaimer This document and information herein is solely for information purposes and must not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. This document may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to media or reproduced in any form, without prior written consent of Cohance Lifesciences This document is based on information obtained from public sources and sources believed to be reliable and information contained in this presentation concerning our industry, competitive position and the markets in which we operate is based on information from independent industry and research organizations, other third-party sources and management estimates Under no circumstances shall Cohance Lifesciences or its employees, consultants, agents or representatives be liable for any costs, expenses, losses, claims, liabilities, or other damages (whether direct, indirect, special, incidental, consequential, or otherwise) that may arise from, or be incurred in connection with, the content or any use thereof Table of Contents Executive Business and Awards & Business wise Annexure summary Financial Recognition Strategy performance and ESG 04 06 14 19 30 Executive Summary Executive Summary Executive Summary – Q2FY27 and H1FY27 Q2FY27: Sequential recovery gaining traction; integrated capabilities strengthening the growth platform  Q2 delivered a clear sequential recovery, with revenue up ~13% QoQ and adjusted EBITDA margin improving to 10% from 2% in Q1, demonstrating progress from the Q1  Strategic Progress: One Cohance integration is driving operational and commercial progress across businesses Pharma CDMO: • In Small Molecules, the order and reload position for Q3 and Q4 has improved materially. Secured two new commercial and one late- stage programme with large global pharma customers, strengthening relationships and medium-term growth opportunities • In nucleic acid business, Sapala’s strong performance is supported by increasing integration of its specialised chemistry and customer relationships with Cohance’s development and manufacturing network. API+: API+ revenue grew YoY, supported by selective pricing actions, while lower API volumes, shipment phasing and higher raw-material costs impacted margins. Specialty Chemicals: Specialty Chemicals declined YoY due to lower AgChem volumes, pricing pressure and programme phasing, while Performance Materials remained relatively stable.  Focused on expanding customer value-chain participation and improving programme conversion through integrated development-to- manufacturing capabilities, including bioconjugation, ADC payload-linkers and R&D infrastructure.  Will maintain disciplined capital allocation, with investments phased based on customer visibility, project readiness and expected returns. FY27 Outlook: Stronger H2 expected  H2FY27 revenue and EBITDA expected to grow YoY, supported by continued recovery and progressive integration of Cohance’s capabilities to unlock platform potential. H2 focus is on improving revenue mix and utilisation to support progressive margin recovery.  H2 is expected to be stronger than H1, driven by Small Molecule deliveries, API+ resilience and Sapala growth, with improved revenue mix and utilisation supporting EBITDA recovery. Proposed Capex  Company plans to announce investments in capex towards building capabilities in adjacencies and R&D to unlock the full potential of the One Cohance platform. Business Financial Performance BUSINESS AND FINANCIAL PERFORMANCE Q2FY27: Q2 Delivered Sequential Growth Q2FY27 performance:  Q2FY27 revenue declined 14.2% YoY to INR 4,767 Mn, due to lower Pharma CDMO and AgChem contributions and an unfavourable business and product mix. Q2 delivered 12.9% 5.0% 33.6% 12.9% sequential revenue growth and EBITDA margins of 9.6% Revenue growth (QoQ) API+ growth (YoY) Sapala revenue growth  Pharma CDMO down 27.4% YoY in Q2 and 32.7% in H1; sequential recovery expected (YoY) to continue in H2  Our Niche technology share contributed 13.7% of revenues INR 4.77 Bn INR 458 Mn* INR 75 Mn*  API+ segment grew 5% YoY, thus continuing to provide resilience. API+ revenue grew Total Revenue Adjusted EBITDA Adjusted Profit/(loss) after Tax YoY, supported by selective pricing actions, while lower API volumes, shipment phasing and higher raw-material costs impacted margins 70.8% 9.6% 13.7%  Nucleic Acid business (Sapala) grew 33.6% YoY in Q2 driven by strong demand for specialised nucleic-acid building blocks, with no early Phase III supplies contribution Gross Margins EBITDA% excl. one time Niche Tech as % of revenue  Specialty Chemicals revenue declined by 40.6% YoY, due to lower AgChem volumes, pricing pressure and programme phasing, while Performance Materials remained relatively stable. Q2FY27 Segmental Revenue (YoY) – CDMO# share at 44%  Gross margins contracted to 70.8%, down 378 basis points YoY. Margins impacted by unfavourable product mix, lower AgChem contribution, weaker Small Molecule revenue conversion and API+ raw-material inflation, partly offset by Sapala and Formulations Pharma CDMO  Adjusted EBITDA for Q2 FY27 was INR 458 Mn, with margins at 10%.  Adjusted PAT also returned to positive territory during the quarter. Healthy cash generation in H1FY27 API +  Free cash flow of INR 885 Mn generated during the quarter. Cash on books stood at INR 2,943 Mn, maintaining a healthy liquidity position  INR 1,080 Mn capex deployed in H1, as we continued investing in capabilities required Speciality for future growth Chemicals Note: 1) Adjusted EBITDA is after One-time adjustment for ESOP, Merger and acquisition costs of INR 68 Mn in Q2FY27 Vs INR 55 Mn in Q2FY26 7 #CDMO includes Pharma CDMO and Specialty Chemicals 2) Adjusted PAT is after One-time adjustment for ESOP, Merger and acquisition costs (Net of tax) BUSINESS AND FINANCIAL PERFORMANCE Q2FY27 Consolidated Financial Results • In Q2, CDMO (Pharma CDMO + Specialty Chemicals) share was 44%, only API+ business saw growth. Niche tech contribution stood at 13.7% • Gross margins contracted by 378 bps YoY due to an unfavourable product mix, lower AgChem contribution, weaker Small Molecule revenue conversion and API+ raw- material inflation, partly offset by Sapala and Formulations • Adjusted EBITDA margin improved to 9.6% from 2.2% in Q1 Particulars Q2FY27 Q1FY27 Q2FY26 QoQ YoY Revenue from Operations 4,767 4,223 5,556 12.9% -14.2% Material costs / COGS (1,391) (1,203) (1,411) Material Margin 3,376 3,020 4,145 11.8% -18.6% Material Margin % 70.8% 71.5% 74.6% Manufacturing Expenses (1,059) (934) (1,019) Employee Cost (1,535) (1,331) (1,267) Other Expenses (428) (743) (630) Total Expenses (3,022) (3,008) (2,916) EBITDA (Reported) 354 12 1,229 2841.7% -71.2% EBITDA (Reported) % 7.4% 0.3% 22.1% FX MTM gain 36 54 7 One-time expenses 68 26 55 EBITDA (Adjusted) 458 92 1,291 397.8% -64.5% EBITDA (Adjusted) % 9.6% 2.2% 23.2% Depreciation & Amortization (502) (494) (440) Finance costs (84) (68) (87) Other income 89 68 130 Profit/(loss) Before Tax (Adjusted) (39) (402) 89 [Showing first 8,000 characters — download PDF for full document]